• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

MIT researchers send drug-ferrying nanoparticles across the blood-brain barrier

May 29, 2018 By Sarah Faulkner

Image courtesy of MIT

Researchers at the Massachusetts Institute of Technology demonstrated in an animal study that nanoparticles shuttling two different cancer drugs could effectively cross the blood-brain barrier and target tumor cells.

The team of scientists evaluated the drug combination in mice that had gliobastoma – an aggressive form of brain cancer that is notoriously hard to treat.

The researchers loaded liposomes with two drugs: one in the particle’s outer shell and one inside the particle’s inner core. Then, they coated the liposomes with a transferrin, a protein designed to help send the particles through the blood-brain barrier and aggregate at the site of the tumor.

“What is unique here is we are not only able to use this mechanism to get across the blood-brain barrier and target tumors very effectively, we are using it to deliver this unique drug combination,” senior author Paula Hammond told MIT News.

The researcher chose to combine a chemotherapy drug, temozolomide, with an investigational bromodomain inhibitor. Because their delivery approach targeted tumor cells, the scientists didn’t need to worry about the toxic side effects associated with systemic administration of temozolomide.

Researchers hypothesize that bromodomain inhibitors interfere with a cell’s ability to repair damage to its genetic makeup. Together, the temozolomide and the bromodomain inhibitor worked to interrupt the cell’s DNA-repair mechanism and then directly attack the cell’s DNA.

In a mouse study published in Nature Communications, the MIT researchers showed that the nanoparticles’ outer layer degrades once the liposomes reach the tumor cells, delivering the bromodomain inhibitor. After 24 hours, temozolomide is unleashed from the particle’s inner core.

Beyond proving that their drug-delivery method was effective, the researchers also showed that the nanoparticles coated with transferrin were more powerful than other treatments – the mice treated with transferrin-coated particles lived twice as long as the mice that were treated with uncoated particles or injected with temozolomide or the bromodomain inhibitor.

“This was really a proof-of-concept study [showing] that we can deliver novel combination therapies using a targeted nanoparticle system across the blood-brain barrier,” lead author Fred Lam said, according to MIT News.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Neurological, Oncology, Pharmaceuticals, Preclinical Trials, Research & Development Tagged With: Massachusetts Institute of Technology

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS